コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ts of the small metabolites were analyzed by proton magnetic resonance spectroscopy.
2 of fluoxetine treatment, 20 mg/day, by using proton magnetic resonance spectroscopy.
3 nd subcortical nuclei/regions with 1.5-tesla proton magnetic resonance spectroscopy.
4 ing, and after ketamine administration using proton magnetic resonance spectroscopy.
5 FC of 19 AD, 19 MCI, and 28 HC with in vivo proton magnetic resonance spectroscopy.
6 nd left striatum were assessed using 3-Tesla proton magnetic resonance spectroscopy.
7 onance imaging; IHCL was assessed by in vivo proton magnetic resonance spectroscopy.
8 and intramyocellular lipid were assessed by proton magnetic resonance spectroscopy.
9 and muscle lipid (intramyocellular lipid) by proton magnetic resonance spectroscopy.
10 hepatic triglyceride content, as measured by proton magnetic resonance spectroscopy.
11 ipid and HTG contents were measured by using proton magnetic resonance spectroscopy.
12 cortex metabolite levels were measured using proton magnetic resonance spectroscopy.
13 hite, 48.3% black, and 17.5% Hispanic) using proton magnetic resonance spectroscopy.
14 d glutamate concentrations is possible using proton magnetic resonance spectroscopy.
15 nonalcoholic fatty liver disease (NAFLD) by proton magnetic resonance spectroscopy ((1) H-MRS) was e
16 trahepatic triglyceride content (IHTG) using proton magnetic resonance spectroscopy ((1) H-MRS), abdo
17 this article is to review and synthesize the proton magnetic resonance spectroscopy ((1)H MRS) and po
21 rs, underwent neuropsychological assessment, proton magnetic resonance spectroscopy ((1)H MRS) examin
26 nal magnetic resonance imaging (rs-fMRI) and proton magnetic resonance spectroscopy ((1)H MRS) were p
27 hippocampal metabolites were measured using proton magnetic resonance spectroscopy ((1)H MRS), and h
28 (GPC+PC)) in bipolar disorder using in vivo proton magnetic resonance spectroscopy ((1)H MRS), espec
29 study, we address this need by presenting a proton magnetic resonance spectroscopy ((1)H-MRS) acquis
31 Liver fat can be non-invasively measured by proton magnetic resonance spectroscopy ((1)H-MRS) and fi
32 skeletal muscle as measured by using in vivo proton magnetic resonance spectroscopy ((1)H-MRS) and wh
34 ting Stroop task and single-voxel J-resolved proton magnetic resonance spectroscopy ((1)H-MRS) in the
39 o test the ability of single voxel localized proton magnetic resonance spectroscopy ((1)H-MRS) to rel
43 he proton density fat fraction (PDFF), using proton magnetic resonance spectroscopy ((1)H-MRS), inste
49 is study was undertaken to determine whether proton magnetic resonance spectroscopy (1H MRS) measures
52 serial magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H-MRS) as stand
56 investigated the use of long-echo time (TE) proton magnetic resonance spectroscopy (1H-MRS) to measu
60 ely quantify information provided by in vivo proton magnetic resonance spectroscopy (1HMRS), an emerg
61 is, and magnetic resonance imaging including proton magnetic resonance spectroscopy and diffusion wei
63 ed with high-resolution magic angle spinning proton magnetic resonance spectroscopy, and afterwards w
64 ctroencephalography, magnetoencephalography, proton magnetic resonance spectroscopy, and functional m
65 trations of N-acetylaspartate, measured with proton magnetic resonance spectroscopy; and cognition, a
67 in vivo in patients with schizophrenia using proton magnetic resonance spectroscopy at 7T, which allo
68 evels were measured by means of quantitative proton magnetic resonance spectroscopy at three time poi
69 ht depressed patients were measured by using proton magnetic resonance spectroscopy before and after
70 ffusion tension imaging, functional MRI, and proton magnetic resonance spectroscopy, can detect non-f
71 fferences in brain metabolism as depicted by proton magnetic resonance spectroscopy data and pharmaco
73 Ten patients with FM underwent 2 sessions of proton magnetic resonance spectroscopy (H-MRS) and 2 ses
74 we investigated cellular neurochemistry with proton magnetic resonance spectroscopy imaging ((1)H-MRS
76 eria), brain magnetic resonance imaging, and proton magnetic resonance spectroscopy imaging (1H-MRSI)
77 t multi-center study (four centers), we used proton magnetic resonance spectroscopy in 51 children wi
78 nterior cingulate cortex (ACC) using 3-Tesla proton magnetic resonance spectroscopy in 75 participant
79 and glutamate/glutamine, were quantified by proton magnetic resonance spectroscopy in PMd and SMA in
80 main goal is to illustrate the potential of proton magnetic resonance spectroscopy in renal oncology
81 ng GABA and GLX (glutamate + glutamine) with proton magnetic resonance spectroscopy in the dorsal ant
83 ent studies investigating schizophrenia with proton magnetic resonance spectroscopy including the fir
85 ced increase in the area under the curve for proton magnetic resonance spectroscopy lactate/N-acetyl
87 en PPA and Alzheimer's disease suggests that proton magnetic resonance spectroscopy may help to diffe
88 ole of neurotransmitter changes, measured by proton magnetic resonance spectroscopy, may inform the m
90 ssion using two complementary methodologies, proton magnetic resonance spectroscopy (MRS) and tissue
98 nance imaging (MRI; hippocampal volume)- and proton magnetic resonance spectroscopy (MRS; N-acetylasp
99 nflammation, neuropsychological testing, and proton-magnetic resonance spectroscopy (MRS)-based metab
106 ols underwent pressure-pain testing and a 3T proton magnetic resonance spectroscopy session in which
107 ntrols underwent pressure pain testing and a proton magnetic resonance spectroscopy session in which
108 ion of GluCEST and a similar increase in the proton magnetic resonance spectroscopy signal of glutama
112 onclude with suggestions for possible future proton magnetic resonance spectroscopy studies in OCD.
115 magnetic resonance imaging and single-voxel proton magnetic resonance spectroscopy study at the Depa
117 The present study employed state-of-the-art proton magnetic resonance spectroscopy techniques to mea
123 s from the Dallas Heart Study also underwent proton magnetic resonance spectroscopy to measure hepati
132 al volumes, rate of hippocampal atrophy, and proton magnetic resonance spectroscopy were assessed on
133 tabolic variables and liver fat (measured by proton magnetic resonance spectroscopy) were measured.
134 was elevated in the two cases who underwent proton magnetic resonance spectroscopy when they were di
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。